Cohance Lifesciences Limited (BOM:543064)

Market Cap	107.08B -62.4%
Revenue (ttm)	10.79B +2.9%
Net Income	606.40M -78.3%
EPS	2.35 -78.5%
Shares Out	n/a
PE Ratio	176.58
Forward PE	29.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	92,190
Average Volume	177,703
Open	289.60
Previous Close	291.80
Day's Range	276.05 - 294.80
52-Week Range	276.05 - 1,246.85
Beta	n/a
RSI	21.80
Earnings Date	Feb 12, 2026

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,212
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In fiscal year 2025, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.